Breakthrough T1D Funded Researcher Receives Prestigious Jacobus Prize
Mark Atkinson, Ph.D., a longtime Breakthrough T1D-funded researcher, is the recipient of 2019 Jacobus Prize for his research into the…
ViaCyte Does it Again: Insulin Production in People with T1D
ViaCyte, a beta cell replacement company long supported by Breakthrough T1D, has shown—for the first time ever—that its PEC-Direct therapy…
EASD Brings World-Renowned Minds to Barcelona
For 55 years, leading researchers from around the world have gathered for the annual meeting of the European Association for…
Breakthrough T1D Clinical Trial Results Announced at the 55th EASD Meeting
A protein, called glucokinase (or GK), acts as a key regulator of sugar levels in the body. If blood glucose…
FDA Approves Xeris Pharmaceuticals’ Glucagon to Treat Severe Hypoglycemia
On Tuesday, the type 1 diabetes (T1D) community got a helping hand in their ability to avoid severe hypoglycemia when…
Breakthrough T1D Launches First Center of Excellence, Aiming to Accelerate Type 1 Diabetes Research
Breakthrough T1D today launched its first Center of Excellence, a new research and funding model aimed at accelerating leading type…
Semma Therapeutics, Backed by the T1D Fund, Acquired by Major Biopharma Company
In an exciting step forward in type 1 diabetes (T1D) research and development and for people with T1D, on September…
Breakthrough T1D Innovative Clinical Trial Design Workshop
BMC Medicine 16: 29 (2018)
Breakthrough T1D Hosts 3D Bioprinting Workshop for Type 1 Diabetes
Breakthrough T1D is committed to developing cell replacement therapies that will one day offer cures for type 1 diabetes (T1D).…
Triple Therapy in T1D: Breakthrough T1D Researchers Launch a Clinical Trial
Since its discovery nearly 100 years ago, insulin has been the only effective treatment for type 1 diabetes (T1D). Improvements…
